TD Cowen analyst Dan Brennan raised the firm’s price target on Grail (GRAL) to $69 from $65 and keeps a Buy rating on the shares. The firm said they posted a modest beat butthe focus remains on ASCO data where NHS-Galleri and Pathfinder 2 data will be presented.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRAL:
- Daniel Brennan Reiterates Buy on Strong Galleri Momentum, Clinical Catalysts, and Raises Price Target to $69
- Grail reports Q1 EPS ($2.29), consensus ($1.96)
- Grail initiated with a Neutral at Mizuho
- Grail initiated with a Neutral at Piper Sandler
- Grail announces collaboration with Epic to bring Galleri test to EHR platforms